Cai Zhiyou
Department of Neurology, The Lu'an Affiliated Hospital of Anhui Medical University, Lu'an People's Hospital, Lu'an, Anhui 237005, P.R. China.
Mol Med Rep. 2014 May;9(5):1533-41. doi: 10.3892/mmr.2014.2040. Epub 2014 Mar 11.
Activated monoamine oxidase (MAO) has a critical role in the pathogenesis of Alzheimer's disease (AD), including the formation of amyloid plaques from amyloid β peptide (Aβ) production and accumulation, formation of neurofibrillary tangles, and cognitive impairment via the destruction of cholinergic neurons and disorder of the cholinergic system. Several studies have indicated that MAO inhibitors improve cognitive deficits and reverse Aβ pathology by modulating proteolytic cleavage of amyloid precursor protein and decreasing Aβ protein fragments. Thus, MAO inhibitors may be considered as promising therapeutic agents for AD.
活化的单胺氧化酶（MAO）在阿尔茨海默病（AD）的发病机制中起关键作用，包括由淀粉样β肽（Aβ）产生和积累形成淀粉样斑块、神经原纤维缠结的形成，以及通过破坏胆碱能神经元和胆碱能系统紊乱导致认知障碍。多项研究表明，MAO抑制剂可通过调节淀粉样前体蛋白的蛋白水解切割和减少Aβ蛋白片段来改善认知缺陷并逆转Aβ病理状态。因此，MAO抑制剂可被视为治疗AD的有前景的治疗药物。
